SkinBioTherapeutics PLC's (LON:SBTX) Stuart Ashman talks to Proactive London about their two recent announcements, initiating a two-year research programme with the University of Manchester to identify new potential treatments and products targeting inflammation.
The firm also announced today a partnership with them to explore the use of bacteria, including its own breakthrough lysate, SkinBiotix, in oral care.